Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1932 1
1934 1
1939 2
1941 2
1942 2
1943 1
1944 2
1945 1
1946 13
1947 14
1948 21
1949 21
1950 17
1951 26
1952 20
1953 34
1954 42
1955 45
1956 52
1957 102
1958 147
1959 134
1960 178
1961 191
1962 246
1963 246
1964 270
1965 215
1966 237
1967 260
1968 321
1969 330
1970 370
1971 488
1972 494
1973 479
1974 559
1975 922
1976 1019
1977 1039
1978 1064
1979 1093
1980 1258
1981 1230
1982 1305
1983 1564
1984 1464
1985 1609
1986 1692
1987 1850
1988 1985
1989 2366
1990 2397
1991 2334
1992 2388
1993 2477
1994 2620
1995 2540
1996 2744
1997 2665
1998 2739
1999 2772
2000 2796
2001 2980
2002 3377
2003 3496
2004 3615
2005 3882
2006 3990
2007 3974
2008 4036
2009 4116
2010 4242
2011 4370
2012 4675
2013 4863
2014 4902
2015 4970
2016 4976
2017 4508
2018 4465
2019 4443
2020 4788
2021 5180
2022 4895
2023 4596
2024 1673

Text availability

Article attribute

Article type

Publication date

Search Results

145,766 results

Results by year

Filters applied: . Clear all
Page 1
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW. Moreno C, et al. Haematologica. 2022 Sep 1;107(9):2108-2120. doi: 10.3324/haematol.2021.279012. Haematologica. 2022. PMID: 35021599 Free PMC article. Clinical Trial.
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. ...In this f …
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab ( …
Chlorambucil.
[No authors listed] [No authors listed] 2017 Oct 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Oct 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643532 Free Books & Documents. Review.
Chlorambucil is an orally administered alkylating agent which is currently used in the therapy of chronic lymphocytic leukemia, Hodgkin and non-Hodgkin lymphomas, and rarely in severe autoimmune conditions including rheumatoid arthritis, uveitis and ne …
Chlorambucil is an orally administered alkylating agent which is currently used in the therapy of chronic lymphocytic …
Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.
Vidal L, Gurion R, Ram R, Raanani P, Bairey O, Robak T, Gafter-Gvili A, Shpilberg O. Vidal L, et al. Leuk Lymphoma. 2016 Sep;57(9):2047-57. doi: 10.3109/10428194.2016.1154956. Epub 2016 Mar 16. Leuk Lymphoma. 2016. PMID: 26980554 Review.
Randomized clinical trials that compared chlorambucil to different regimens, for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not support an overall survival (OS) benefit. ...Meta-analysis of 18 trials that compare …
Randomized clinical trials that compared chlorambucil to different regimens, for patients with chronic lymphocytic l …
Chronic lymphocytic leukemia.
Rozman C, Montserrat E. Rozman C, et al. N Engl J Med. 1995 Oct 19;333(16):1052-7. doi: 10.1056/NEJM199510193331606. N Engl J Med. 1995. PMID: 7675049 Review. No abstract available.
Chlorambucil in chronic lymphocytic leukemia: mechanism of action.
Begleiter A, Mowat M, Israels LG, Johnston JB. Begleiter A, et al. Leuk Lymphoma. 1996 Oct;23(3-4):187-201. doi: 10.3109/10428199609054821. Leuk Lymphoma. 1996. PMID: 9031099 Review.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries but the clinical presentation and rate of disease progression are highly variable. When treatment is required the most commonly used therapy is the nitrogen mustard alkylating …
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries but the clinical presentation and r …
Chronic lymphocytic leukemia.
Rundles RW, Moore JO. Rundles RW, et al. Cancer. 1978 Aug;42(2 Suppl):941-5. doi: 10.1002/1097-0142(197808)42:2+<941::aid-cncr2820420717>3.0.co;2-1. Cancer. 1978. PMID: 688176
Chronic lymphocytic leukemia (CLL) is the commonest type of leukemia seen in Western countries. ...In the great majority of patients, the disease can be controlled for 6 to 10 or more years with simple regimens using chlorambucil or cyclophosphamide, o …
Chronic lymphocytic leukemia (CLL) is the commonest type of leukemia seen in Western countries. ...In the great majorit …
Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.
Goede V, Eichhorst B, Fischer K, Wendtner CM, Hallek M. Goede V, et al. Leuk Lymphoma. 2015 Jun;56(6):1585-92. doi: 10.3109/10428194.2014.963077. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25219593 Review.
For many decades, chlorambucil was the standard of care for chronic lymphocytic leukemia (CLL), but meanwhile has been replaced by purine analog-based chemoimmunotherapy. ...Starting from the past role of chlorambucil in CLL treatment, we here r …
For many decades, chlorambucil was the standard of care for chronic lymphocytic leukemia (CLL), but meanwhile ha …
Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.
Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, Achenbach SJ, Call TG, Parikh SA, Ding W, Kay NE, Shanafelt TD. Strati P, et al. Haematologica. 2015 Sep;100(9):1180-8. doi: 10.3324/haematol.2015.128793. Epub 2015 Jun 18. Haematologica. 2015. PMID: 26088927 Free PMC article. Clinical Trial.
Between January 1995 and June 2014, 49 of 4,024 (1.2%) patients with chronic lymphocytic leukemia (n=44) or monoclonal B-cell lymphocytosis (n=5) had a renal biopsy: 34 (69%) for renal insufficiency and 15 (31%) for nephrotic syndrome. ...All ca …
Between January 1995 and June 2014, 49 of 4,024 (1.2%) patients with chronic lymphocytic leukemia (n=44) or monoclonal …
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.
Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Michallet AS, et al. Haematologica. 2018 Apr;103(4):698-706. doi: 10.3324/haematol.2017.170480. Epub 2018 Feb 1. Haematologica. 2018. PMID: 29419437 Free PMC article. Clinical Trial.
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. ...Rituximab plus bendamustine may be a valuable first-line option for fludar …
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible pa …
145,766 results
You have reached the last available page of results. Please see the User Guide for more information.